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Abstract: 
Most drugs are taken orally. For those intended to act systemically, a significant fraction of the dose can be 
eliminated during its first passage through a sequence of organs before entry into the general circulation. For 
some drugs, the degree of first-pass elimination can be large enough such that oral bioavailability is 
significantly reduced, with the consequent potential for a reduced clinical response. Of these first-pass 
eliminating organs, the small intestine and liver are the most commonly implicated, in part because they express 
the highest levels of drug-metabolizing enzymes. For several drugs whose major route of elimination occurs via 
CYP3A-mediated metabolism, the extent of first-pass metabolism in the small intestine can rival that in the 
liver. As such, alterations in enteric CYP3A activity alone can significantly influence oral bioavailability. The 
most extensively studied xenobiotic shown to inhibit only enteric CYP3A is grapefruit juice, the consequences 
of which can be clinically significant. Although much information has been gained regarding the grapefruit 
juice effect, progress in the relatively understudied area of drug-diet interactions continues to be sluggish and 
reactive. In stark contrast, the potential for drug-drug interactions involving any new therapeutic agent must be 
evaluated, prospectively, before market introduction. To prospectively elucidate mechanisms underlying drug-
diet interactions, a multidisciplinary, translational research approach is required, which capitalizes on the 
collective expertise of drug metabolism scientists and natural products chemists. Such an approach would allow 
proper between-study comparisons, and ultimately provide conclusive information as to whether specific 
dietary substances can be taken safely with certain medications. 
Keywords: cranberry, CYP3A, drug—diet interactions, drug—fruit juice interactions, first-pass metabolism, 
furanocoumarins, grapefruit, natural product, oral bioavailability, pomegranate 
 
Article: 
1. Introduction 
The oral route continues to serve as the most popular, convenient and generally safest means of drug 
administration. However, this route is not necessarily the most efficient, particularly for systemically acting 
drugs, due to the many anatomical and physiological barriers drugs encounter from the time of ingestion until 
the time of entry into the general circulation. As a consequence, before the drug reaches the circulation and 
exerts its effects in the target tissue(s), significant loss of the original dose can occur as the drug passes, for the 
first time, through the following sequence of organs: the gastrointestinal (GI) tract, the liver and the 
cardiopulmonary system (Figure 1). Processes that can lead to significant loss of active drug include incomplete 
release from the dosage form, degradation in the GI lumen, poor permeation across the GI epithelial barrier, 
active efflux into the GI lumen, biliary excretion, and metabolism. Of these processes, only metabolism can 
occur in all of the aforementioned organs. 
 
Metabolism represents the primary means by which the body eliminates xenobiotics, including the majority of 
drugs. Enzymatic alteration of the drug usually produces Inactive metabolItes with increased water solubility to 
facilitate excretion. For many drugs, the extent of conversion to inactive metabolites can be large enough such 
that circulating levels of active drug are significantly reduced, which in turn can lead to a significant decrease in 
pharmacological activity and a reduced clinical response. Drugs with a narrow therapeutic window that undergo 
extensive presystemic metabolism are especially vulnerable to a reduced clinical response. Of the first-pass 
organs of elimination, the liver is the most commonly implicated, in part because it contains the highest levels 
of drug-metabolizing enzymes. Next to the liver, the intestinal mucosa undoubtedly represents the most 
important extrahepatic site of drug biotransformation 11]. Several of the drug-metabolizing enzymes expressed 
In hepatocytes are also expressed in the epithelial cells that line the small intestinal mucosa (enterocytes), 
including both phase I (oxidative and reductive) and phase II (conjugative) enzymes. Of the phase I enzymes, 
the CYPs are the most prominent, with the CYP3A subfamily, composed primarily of CYP3A4 and the poly-
morphic CYP3A5 in adults 12,31, representIng the largest portion (80%) of total CYP content in the proximal 
small intestine 141. So far, only CYP3A has been shown conclusively to have clinical relevance, as is discussed 
in greater detail in later sections of this review. Other phase I enzymes expressed in the human small intestine 
include carboxylesterases and epoxide hydrolases; the former are believed to contribute to the first-pass 
conversion of the prodrug irinotecan to its active chemotherapeutic metabolite, SN-38 151. Enteric phase II 
enzymes include UDP-glucuronosyl transferases (UGTs), sulfotransferases (SULTs), N-acetyl transferases and 
glutathione S-transferases. Of these enzymes, the UGTs and SULTs are the most commonly implicated in the 
metabolism of drugs. Each of the various UGT and SULT subfamilies are described in detail in several 
excellent reviews 16-9J. 
 
2. Clinical relevance of intestinal metabolism 
The small intestine represents the first in the serIes of organs that drugs encounter when taken orally. As such, 
for drugs that are absorbed by the transcellular route, the opportunity exists for first-pass metabolism, the extent 
of whIch can have clinical ramifications. Of the numerous drug-metabolizing enzymes expressed in the 
intestinal mucosa, the CYP3A subfamily Is the most extensively studied, due in part to its established role as a 
major contributor to the interindividual variation in drug oral bioavailability, as well as a major site for drug—
drug, and especially drug—diet, interactions. 
 
2.1 Influence on oral bioavailability 
The oral bioavailability (Foral) of a drug refers to the fraction of the oral dose that reaches the systemic 
circulation In the unchanged form. Because metabolism is frequently the major cause of first-pass drug 
elimination, Forai is often used as a measure of the extent of first-pass metabolism 1101. Foral can be calculated 
from the ratio of the area under the concentration versus time curve following oral administration (AUCoral) to 
that following intravenous administration (AUCiv) and correcting for dose (Equation 1): 
 
When drug-eliminating organs are arranged in series, such as the small intestine and liver (Figure 1), Foral may 
also be viewed as the product of the fractions of the dose that escape metabolism by each organ (Equation 2) 
110J: 
 
 
where, Fabs is the fraction of the oral dose absorbed intact across the apical (luminal) membranes of enterocytes, 
and Fc and FL are the fractIons of the absorbed dose that escape 
 
 
metabolism by the gut and liver, respectively. This simple equation demonstrates the impact of a second 
presystemic site of metabolism on Fora,. For example, if a drug is absorbed into enterocytes intact (Fabs = 
100%), and has an FG of 60% and an FL of 40%, then an Fora, of 24% is predicted, which is roughly half the 
value predicted if only hepatic metabolism were considered (1 x 1 x 40% = 40%). Thus, omission of the 
intestinal component would lead to an overestimation of Forai, which could potentially lead to suboptimal 
dosing and ineffective concentrations at the site(s) of action. For drugs that have a wide therapeutic window, 
this can be remedied simply by increasing the dose. However, for drugs that have a narrow therapeutic window 
and/or exhibit a large interindividual variation in Foral, then optimization of oral drug therapy becomes more 
challenging. Moreover, factors that significantly influence metabolism, including other xenobiotics (either 
pharmaceutically or diet-derived) that induce or inhibit drug-metabolizing enzymes, thus altering FG and/or FL, 
pose further challenges to effective oral drug therapy. 
 
Equation 2 also demonstrates the potential impact of a second presystemic site of metabolism on the 
interindividual variation in Foral. For example, if a drug has an FG that ranges 30 — 60% (twofold range), an FL 
that ranges 20 — 80% (four- fold range), and the extraction efficiencies of the gut and liver vary independently 
(as is the case for CYP3A-mediated metabolism), then Foral will range 6 — 48% (eightfold range), resulting in a 
100% increase in the variation in Foral (if only FL were considered initially). Interestingly, data collected from 
143 pharmacokinetic studies demonstrated a significant inverse correlation between Foral and the interindividual 
variation in Foral, as assessed by the coefficient of variation in Foral [111. This relationship indicates that the 
greater the extent of first-pass extraction, the greater will be the variation in Foral. Therefore, knowledge of the 
degree and variation in the expression of the major intestinal drug-metabolizing enzymes involved in drug 
disposition is essential, as such enzymes can represent a key determinant of the extent of first-pass elimination, 
as well as the interindividual variation in Fora, and the probability and magnitude of drug—drug (or drug—diet) 
interactions [12]. 
 
2.2 Risks of multi-drug regimens 
Multi-drug regimens are common in many industrialized countries, especially among the elderly 1131, and 
among patients with chronic illnesses such as AIDS 1141 and cancer 1151. Because the risk of drug—drug 
interactions increases considerably with the number of concomitant medications, the risk of impaired treatment 
efficacy and/or increased drug-related toxicity will also increase [151. Reported drug—drug interactions in 
clinical practice frequently result from one drug impairing the elimination of another (the target). A reduced 
ability to eliminate the target can lead to an increase in systemic concentrations of the target, with a consequent 
potential for an exaggerated pharmacological or toxic biological response. The CYPs account for almost 50% of 
the overall elimination of commonly prescribed drugs [161. The CYP3A subfamily is believed to participate in 
the metabolism of over half of therapeutic agents that undergo oxidation [16l. Taken together, inhibition of 
CYP3A-mediated metabolism, in the liver and/or small intestine, is a common mechanism underlying many 
drug—drug interactions. Moreover, the extent of inhibition by a comedicant often varies among individuals, 
making it challenging for the clinician to predict the magnitude and severity of the interaction, especially if the 
target drug has a narrow therapeutic window. 
 
In addition to drug—drug interactions, another common concern with individuals taking multiple medications is 
poor adherence to the administration schedule. Associating drug administration with a regular event, such as a 
meal, can improve adherence [17]. A relatively overlooked consequence of this common strategy is an 
interaction between a drug and a dietary substance. General mechanisms underlying the effects of food on drug 
disposition have been well characterized and include delayed gastric emptying, solubilization of drug by food 
and digestive fluids, complexation of drug with food components and alterations in hepatic blood flow [18.19]. 
In addition, because the majority of xenobiotics that enter the body are components of the diet, it follows that 
some of these diet-derived xenobiotics may be capable of modulating drug metabolism in a manner similar to 
therapeutic agents [18,191. Therefore, inhibition of drug metabolism by dietary substances could lead to 
increased concentrations of the target drug and the potential for an exaggerated pharmacological response or 
toxicity. 
 
3. Drug-fruit juice interactions 
One of the most widely studied dietary substances shown unequivocally to inhibit drug metabolism is grapefruit 
juice. As detailed in subsequent sections, the consequences of such drug—grapefruit juice interactions can be 
clinically significant. Accordingly, a major research effort has been launched to characterize the mechanism(s) 
underlying, as well as the specific components that mediate, these interactions. The remainder of this review 
focuses on grapefruit juice and other fruit juices shown to inhibit drug metabolism in vivo and, perhaps more 
importantly, the lessons learned while delineating these relatively understudied types of drug interactions. 
 
3.1 Grapefruit juice 
More than 15 years have passed since the serendipitous observation of a pharmacokinetic interaction between 
the calcium-channel antagonist, felodipine, and grapefruit juice, which was used to mask the taste of ethanol 
during a felodipine—ethanol interaction study [201. Specifically, in patients with borderline hypertension, the 
combination of felodipine and a nontoxicating dose of ethanol resulted in a higher incidence of orthostatic 
hypotension than felodipine alone. Moreover, although plasma felodipine concentrations were not different 
between the two treatments, they greatly 
 
exceeded those observed in other pharmacokinetic studies involving the same dose of drug. After ruling out 
obvious potential causes (e.g., incorrect dose, drug assay problems), the investigators suspected an interaction 
with the grapefruit juice vehicle. A subsequent controlled clinical study confirmed grapefruit juice as the 
causative agent and demonstrated that this drug—diet interaction resulted from the grapefruit juice-mediated 
inhibition of felodipine metabolism 
by CYP3A 121,221. 
 
3.1.1 Inhibition of intestinal CYP3A 
Drug—grapefruit juice interactions are distinct from the majority of drug—drug interactions in that, when the 
juice is consumed in usual volumes, inhibition occurs exclusively in the small intestine. Unlike other major 
CYPs, CYP3A is expressed in high abundance in the small intestine [4], with an expression level and associated 
catalytic activity in the proximal portion that are comparable to those in the liver 123,24]. Hepatic CYP3A 
activity appears to be unaffected by grapefruit juice, as evidenced by a lack of effect on the clearance and half-
life of intravenously administered drugs [22,251, as well as on the intravenous erythromycin breath test [26]. 
The lack of an effect on hepatic CYP3A is believed to be due to dilution of the causative ingredient(s) in portal 
blood to concentrations below their effectIve inhibitory concentrations and/or to extensive binding of the 
causative ingredients to plasma proteins in portal blood [27]. 
 
Enteric CYP3A inhibition by grapefruit juice components include both reversible and mechanism-based modes 
122,28]. In addition, the pivotal investigation by Lown et al. [26] demonstrated that grapefruit juice 
significantly reduced mean enteric CYP3A4 immunoreactive protein content (by ~ 60%), which was measured 
in duodenal pinch biopsies obtained, before and after juice ingestion, from nine healthy volunteers. The 
reduction in CYP3A4 protein was unaccompanied by a decrease in mRNA, which was believed to reflect 
accelerated degradation of the enzyme following mechanism-based inactivation [26]. Moreover, because 
inactivation of the protein is permanent, de novo enzyme synthesis is required to restore CYP3A4 activity. This 
irreversible loss of CYP3A4 protein also explains the prolonged effect of grapefruit juice (~ 3 days) [29-311. 
This striking observation, that a natural product was capable of destroying an endogenous protein in an 
irreversible fashion, further stimulated the identification of the causative ingredients responsible for the 
grapefruit juice effect. 
 
3.1.2 CYP3A inhibitory ingredients 
Flavonoids were originally alleged to be the CYP3A inhibitors contained in grapefruit juice, due to their high 
abundance in the juice and inhibitory effects in vitro 1321. Administration of purified forms of these 
compounds (naringin, quercetin) to human volunteers, however, failed to demonstrate an effect [33-35]. 
Numerous in vitro studies later indicated that furanocoumarins are the major inhibitors, acting by both 
reversible and irreversible mechanisms, with inhibitory constants (IC50, K) in the low micromolar range 
[27,28,36-40]. Bergamottin and 6',7'-dihydroxybergamottin are two abundant, and the most extensively studied, 
furanocoumarins, and each is generally present in grapefruit juice preparations at concentrations well above 
those required to effectively inhibit CYP3A activity in vitro [22,27,28,37,39,401. To gain further mechanistic 
understanding of the major ingredients responsible for the 
 
grapefruit juice effect, the time-dependent absorption and inhibitory properties of bergamottin and 6',7'-
dihydroxybergamottin were compared systematically using a human small intestine-derived cell line (Caco-2), 
modified to express functionally active CYP3A4 1401. A marked difference in both the rate of cell entry and 
onset of inhibition was observed. 6',7'-Dihydroxybergamottin rapidly diffused across the apical membranes of 
cells, within minutes, and effectively inhibited CYP3A4 activity, whereas the more lipophilic bergamottin had a 
much slower rate of entry and a delayed onset of inhibition. These results, which could not be predicted from 
subcellular tissue fractions (e.g., microsomes) or recombinant enzyme, indicated that enteric CYP3A4 is 
maximally inhibited by 6', 7'-dihydroxybergamottin before bergamottin has the opportunity to act, suggesting 
that 6',7'-dihydroxybergamottin represents a major CYP3A inhibitor when grapefruit juice is consumed with a 
rapidly absorbed substrate (e.g., midazolam, felodipine). Indeed, lime juice, which contains bergamottin at a 
concentration exceeding that in grapefruit juice, but no 6',7'-dihydroxybergamottin, had a minimal and 
insignificant effect (~ 20% increase) on average felodipine AUC in healthy volunteers (Table 1) [41J. In 
contrast, a grapefruit juice fraction enriched in 6',7'-dihydroxybergamottin, but with negligible bergamottin, had 
a substantial effect on average felodipine AUC (90% increase) [42]. Most recently, the carbonated beverage, 
Fresca
®
, which contains a high concentration of bergamottin, but no 6',7'-dihydroxybergamottin, had no effect 
on ciclosporin systemic exposure [431, further indicating that bergamottin is not the sole ingredient responsible 
for the grapefruit juice effect, even with a slowly absorbed CYP3A substrate. Furanocoumarin dimers, some of 
which are more potent CYP3A inhibitors than 6',7'-dihydroxybergamottin [39,44[, may represent additional 
major contributors to the grapefruit juice effect. Whether these compounds act as efficiently as 6', 7'-
dihydroxybergamottin remains to be evaluated. 
 
To determine whether furanocoumarins, in aggregate, account for drug—grapefruit interactions in vivo, the 
effects of a novel, food-grade grapefruit juice that was devoid of furanocoumarins (~ 99%) were tested on the 
pharmacokinetics of felodipine in 18 healthy volunteers [45]. As anticipated, relative to regular (sweet) orange 
juice (control), which does not contain furanocoumarins, whole grapefruit juice significantly increased median 
felodipine AUC and Cmax by two- to threefold, while having no effect on terminal half-life. In contrast, the 
modified grapefruit juice had no demonstrable effect on any pharmacokinetic outcome, with a mean felodipine 
concentration—time profile that was superimposable with that of orange juice (Figure 2). This study 
demonstrated, for the first time, that furanocoumarins, in aggregate (and potentially other unidentified bioactive 
compounds that were removed during preparation of the modified juice), mediate the interaction between 
grapefruit juice and the model CYP3A substrate felodipine in vivo. These substances are also likely responsible, 
at least in part, for interactions between grapefruit juice and other drugs that undergo extensive enteric CYP3A-
mediated first-pass metabolism (e.g., several HIV protease inhibitors, immunosuppressants, calcium-channel 
antagonists and 3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors). 
 
3.1.3 Inhibition of intestinal transporters 
Although the aforementioned clinical study established furanocoumarins as mediators of the interaction 
between felodipine and grapefruit juice, such may not be the case for all CYP3A substrates. Unlike felodipine, 
several CYP3A substrates are also substrates for the efflux transporter P-glycoprotein (P-gp), which is located 
on the apical membrane of multiple cell types, including enterocytes. Accordingly, enteric P-gp functions to 
extrude its substrates back into the intestinal lumen. Taken together, inhibition of enteric P-gp activity would be 
expected to enhance drug systemic exposure. Dual CYP3A/P-gp substrates include some immunosuppressants 
(e.g., ciclosporin, tacrolimus, sirolimus), HIV protease inhibitors (e.g., saquinavir, ritonavir) and 
chemotherapeutic agents (e.g., paclitaxel, docetaxel). Whether or not grapefruit juice inhibits enteric P-gp 
activity remains controversial. For example, experiments with Caco-2 cell monolayers demonstrated that diluted 
grapefruit juice, or organic extracts of the juice, inhibited the bidirectional translocation of the nonmetabolized 
P-gp substrates, digoxin [46,47[ and talinolol [481, as well as the dual CYP3A/P-gp substrates, saquinavir and 
vinblastine [49-5i[. However, in human volunteers, grapefruit juice had a negligible effect on the systemic 
exposure of digoxin [52,53[ and decreased, significantly, the systemic exposure of talinolol (by 30%) [541 and 
two other nonmetabolized P-gp substrates, fexofenadine and celiprolol (by 60 and 85%, respectively) [46,55]. 
These apparent in vitro—in vivo inconsistencies were attributed to inhibition by grapefruit juice components of 
an apically located uptake transporter belonging to the organic anion-transporting polypeptide (OATP, or 
SLCO) family. At least one OATP (OATP-B, or OATP2B1) is expressed in enterocytes [56,57]. As such, 
opposite to enteric P-gp, enteric OATP functions to facilitate the absorption of its substrates, which include 
digoxin and fexofenadine [58,59]. Diluted grapefruit juice and some of its components, including 6',7'-
dihydroxybergamottin and bergamottin, were recently reported to inhibit OATP activity in OATP-B-transfected 
human embryonic kidney cells [60]. Collectively, these observations support the contention that, in addition to 
intestinal CYP3A, the net effect of grapefruit juice may depend on the balance of intestinal uptake and efflux 
for certain medications [53]. 
 
3.7.4 Clinical and regulatory implications 
Despite the fact that grapefruit juice acts only at the level of the intestine, the magnitude of the interaction can 
have clinical ramifications. For example, in case reports involving the HMG CoA reductase inhibitors, 
atorvastatin and simvastatin, both of which undergo extensive enteric CYP3A-mediated metabolism, 
consumption of fresh grapefruit was deduced to have caused muscle pain and weakness secondary to elevated 
circulating systemic concentrations of the `statin, [61,62]. Such adverse effects are indicative of statin-
associated rhabdomyolysis, a potential life-threatening skeletal muscle toxicity. Indeed, controlled clinical 
studies have demonstrated that grapefruit juice can significantly increase the systemic exposure of these and 
other statins [63-66]. Additional drug—grapefruit juice interactions shown to result in an enhanced pharmaco-
logical effect include those involving the dihydropyridine calcium-channel antagonists, felodipine, nifedipine 
and nisoldipine (hypotension, increased heart rate), as well as the antiarrhythmic agent, amiodarone 
(proarrhythmia) [67]. As a consequence of these and other potential clinically important outcomes, the labeling 
for some drugs (e.g., amiodarone, verapamil, ciclosporin, sirolimus, simvastatin, lovastatin, felodipine) includes 
warnings or precautionary statements regarding grapefruit juice interaction potential [201]. Ciclosporin, 
sirolimus and other drugs with a narrow therapeutic window are of particular concern because the magnitude of 
the interaction is unpredictable. Such unpredictability is due in part to the large interindividual variation in 
baseline enteric CYP3A content/activity (8- to 10-fold) [26,68] and to the large variation in the composition of 
the active ingredients in different brands, as well as different lots of the same brand, of grapefruit juice 
preparations [36,69.70]. It also follows that, for some drugs, variable enteric P-gp (~ 10-fold) [68] and OATP 
activity would contribute to the variation in response. Several excellent reviews provide a comprehensive 
summary of drugs shown to interact with grapefruit juice, along with the magnitude of the interaction and 
potential clinical outcome [17,22,25,60,71J. 
 
3.2 Other furanocoumarin-containing citrus juices 
The identification of furanocoumarins as major components responsible for drug—grapefruit juice interactions 
suggested that these compounds could be used as marker substances to identify other foods with interaction 
potential. Indeed, juices prepared from two citrus fruits related to the grapefruit have been shown to contain 
several of the same furanocoumarins as grapefruit juice: the Seville (sour) orange and the pomelo [28,72]. 
Accordingly, controlled clinical studies have been conducted to assess whether these juices act in a manner 
similar to grapefruit juice. 
 
3.2.7 Seville orange juice 
The Seville, or sour, orange is used primarily in the preparation of certain confectionaries, such as marmalades 
and candied fruit. It is not commercially available as a beverage due to an extremely sour taste. Nevertheless, 
because juice prepared from the fresh fruit has been reported to contain furanocoumarins at concentrations 
comparable to grapefruit juice [28,72], as proof of principle, the effects of a Seville orange juice have been 
tested on the pharmacokinetics of some CYP3A substrates (Table 1). For example, by randomized crossover 
design, 10 healthy volunteers were given felodipine with a single glass of Seville orange juice, diluted 
grapefruit juice (which contained equivalent total molar concentrations of bergamot- tin and 6',7'-
dihydroxybergamottin), or regular (sweet) orange juice as the control juice [72]. Relative to control, both 
Seville orange juice and grapefruit juice significantly increased average felodipine AUC (by ~ 80 and 90%, 
respectively), although having no effect on terminal half-life. Thus, Seville orange juice appeared to act in a 
manner similar to grapefruit juice, most likely by inhibiting enteric CYP3A via furanocoumarins. Indeed, a 
single glass of Seville orange juice was shown to reduce average immunoreactive CYP3A4 protein content in 
duodenal pinch biopsies (by 40%) obtained from two individuals [73]. 
 
Most recently, a Seville orange juice was tested on the pharmacokinetics of the HIV protease inhibitor and dual 
CYP3A/P-gp substrate, saquinavir [74J. Because the saquinavir—grapefruit juice interaction is modest, 
producing a 50% increase in average AUC [75], 20 volunteers were tested to ensure detection of an interaction 
with Seville orange juice. As anticipated, relative to control (water), Seville orange juice significantly increased 
mean saquinavir AUC (by ~ 70%), with no effect on half-life. These results were inconsistent with those 
observed with another dual CYP3A/P-gp substrate, ciclosporin, which had no interaction with Seville orange 
juice (Table 1) [73]. Because grapefruit juice did have an interaction with the drug (55% increase in mean 
AUC), coupled with the 40% reduction in enteric CYP3A4 immunoreactive protein by Seville orange juice, the 
investigators concluded that enteric CYP3A is not a major contributor to the low For, of ciclosporin (~ 30%) and 
that Seville orange juice is devoid of P-gp inhibitors [73]. Based on observations from the saquinavir study, an 
alternative explanation is that the ciclosporin study was underpowered, as only seven subjects were enrolled. In 
addition, the Seville oranges used in the ciclosporin study could have contained furanocoumarins in aggregate 
concentrations much lower than those used in the saquinavir study, as only 6',7'-dihydroxybergamottin was 
measured in the ciclosporin study (~ 30 µg in both Seville orange and grapefruit juice), and no furanocoumarins 
were measured in the saquinavir study. Indeed, as with grapefruit juice preparations, natural products in general 
are known to vary considerably in their composition of bioactive components 1761. 
 
The effects of a Seville orange juice have also been tested on the pharmacokinetics of another HIV protease 
inhibitor, indinavir [77]. Unlike saquinavir, indinavir has an appreciable Form (65%), and, hence, undergoes 
modest first-pass elimination. Thus, it was not surprising that Seville orange juice, and also grapefruit juice, had 
a negligible effect on indinavir systemic exposure. Again, although the concentration of 6',7'-
dihydroxybergamottin was comparable between the two juices (40 µg), no other furanocoumarin was measured, 
making it difficult to compare to the other drug interaction studies involving Seville orange juice, as well as to 
those involving grapefruit juice. 
 
3.2.2 Pomelo juice 
The pomelo is popular in many Asian countries and is typically consumed as the fresh fruit. Like Seville orange 
juice, at least one juice prepared from the pomelo has been reported to contain furanocoumarins (i.e., 
bergamottin and 6',7'-dihydroxybergamottin) in concentrations comparable to those in grapefruit juice [78]. One 
case has been reported of a potential interaction between tacrolimus and pomelo, in which a renal transplant 
recipient stabilized on tacrolimus exhibited an abnormally high trough concentration [79]. After questioning the 
patient about his recent activities, including dietary changes, and excluding other possible causes, the 
investigators deduced that the increased trough tacrolimus concentration was due to inhibition of intestinal 
CYP3A by furanocoumarins in the pomelo that the patient had consumed the evening prior to blood collection. 
Indeed, after abstaining from pomelo thereafter, the patient returned for another blood draw, and the trough 
concentration had returned to baseline. Based on this in vivo observation, and on in vitro results showing that a 
pomelo extract inhibited CYP3A and P-gp activity 147,78], a controlled clinical study was undertaken to assess 
whether pomelo juice produced an interaction with ciclosporin in 12 healthy volunteers (Table 1) [80]. As 
anticipated, pomelo juice increased modestly, but significantly, the mean AUC and Cmax of ciclosporin, by 20 
and 12%, respectively. Unfortunately, as with the saquinavir—Seville orange juice interaction study, the 
pomelo juice was not characterized for furanocoumarin content, making it impossible to compare these results 
to those from other studies involving furanocoumarin-containing juices. 
 
3.3 Orange juice (sweet) 
Because regular (sweet) orange juice has been reported to have no interaction with some CYP3A substrates, 
including felodipine [211 and ciclosporin 181], some investigators have used this citrus juice as the control 
(rather than water) in drug—grapefruit juice interaction studies to better control for potential physiologic effects 
of the treatment juice, such as carbohydrate and calorie load [45]. To ascertain whether grapefruit juice and 
other fruit juices, including orange juice, inhibit P-gp activity in vivo, a healthy volunteer study was undertaken 
using fexofenadine [46], a P-gp substrate that undergoes negligible metabolism. Relative to water, orange juice 
unexpectedly and significantly decreased the mean AUC and Cmax of fexofenadine (by ~ 70%) (Table 1), as did 
grapefruit juice (see Section 3.1.3). In addition, similar to an extract of grapefruit juice, an extract of orange 
juice was shown to inhibit OATP activity in rat and human OATP-transfected HeLa cells [46]. Because 
fexofenadine is a known OATP substrate, the mechanism underlying the fexofenadine—orange juice interaction 
was postulated to involve inhibition of OATP-mediated uptake. This mechanism could also underlie the orange 
juice-mediated reduction (80 — 90%) in the systemic exposure of the nonmetabolized P-gp substrate, celiprolol 
(Table 1) 182]. Because orange juice does not contain furanocoumarins, other components must be responsible 
for this `orange juice effect,. Candidate inhibitors include polymethoxylated flavones, which are abundant in 
sweet orange, but not grapefruit juice, and have been demonstrated to inhibit OATP-B, as well as P-gp, activity 
in various in vitro cell systems [49,51,60,83]. Unlike furanocoumarins, orange juice/polymethoxyflavones have 
been reported to have no inhibitory effect towards CYP3A activity in both human liver [83] and intestinal [451 
microsomes. 
 
In contrast to the aforementioned clinical studies, Koitabashi et al. [84] recently reported, in 14 healthy 
volunteers, that multiple glasses of orange juice significantly increased the systemic exposure (50% increase in 
mean AUC), but not half-life, of the OATP substrate, pravastatin (Table 1). Pravastatin, which undergoes 
minimal metabolism, is a substrate for not only OATP, but also P-gp and two other efflux transporters, multi-
drug resistance-associated protein 2 (MRP2) and breast cancer-resistance protein (BCRP) [851, both of which 
have been detected in the apical membranes of human enterocytes. In addition to their ability to inhibit P-gp 
activity, orange juice/polymethoxyflavones have been shown to inhibit MRP2 activity in MRP2-transfected 
porcine kidney epithelial cells [51]. Whether these compounds inhibit BCRP activity remains to be determined. 
Studies in rats, in which orange juice also enhanced pravastatin systemic exposure, showed that changes in 
neither intestinal pH nor carbohydrate load altered the pharmacokinetics of pravastatin 184], thus ruling out 
these potential physicochemical effects of orange juice. Taken together, net inhibition of efflux, rather than 
uptake, by orange juice components could explain this interaction. Clearly, further investigation is required to 
discern the mechanism underlying the pravastatin—orange juice interaction in humans. 
 
Collectively, these in vitro and in vivo observations involving sweet orange juice further support the notion that, 
in addition to metabolism, the net effect of dietary substances on drug disposition may depend on the balance of 
intestinal uptake and efflux ]53]. Moreover, this balance of enzymes/transporters may vary with substrate. 
Finally, none of the orange juice products used in any of these clinical studies was characterized for potential 
causative ingredients, again precluding interstudy comparisons. 
 
3.4 Cranberry juice 
Cranberry juice, a popular beverage since the 1930s, has been promoted heavily for its health benefits, 
including prevention of urinary tract infections (UTIs) [86,87], which account for > 11 million physician visits 
annually in the US [88]. Scientific evidence indicates that the prophylactic nature of cranberry juice is related to 
its antiadherent properties, rather than to urinary acidification [86,87,89]. Escherichia coil, the most common 
cause of UTIs, have hair-like fimbria that protrude from their surface. The fimbria produce adhesins that attach 
to receptors on uroepithelial cells. Compounds identified in cranberries that inhibit these adhesions include 
proanthocyanidins (condensed tannins), which are found in relatively high concentrations in Vaccinum berries 
(cranberries and blueberries) [90]. Finally, regular consumption of cranberry juice was effective in the 
prevention of UTI caused by antibiotic-resistant strains of E. coil [89]. Thus, cranberry juice could represent a 
natural alternative for women and the elderly with recurrent UTIs, who often require long-term antimicrobial 
therapy, which can increase the emergence of resistant strains of the causative organism(s). 
 
A recent in vivo study in rats indicated that components in cranberry juice are capable of inhibiting enteric 
CYP3A activity (Table 1) [91]. Following oral administration of the CYP3A substrate nifedipine, cranberry 
juice appeared to inhibit enteric, but not hepatic, first-pass metabolism, as evidenced by a lack of an effect on 
drug systemic half-life [91]. Moreover, relative to control (saline), cranberry juice significantly increased the 
average AUC of oral nifedipine to an extent comparable to that with grapefruit juice 60%). Because species 
differences in drug-metabolizing enzymes are known to exist, comparable clinical studies are warranted to 
ascertain whether or not cranberry juice can enhance the systemic exposure of clinically relevant CYP3A 
substrates in humans. The single published clinical study so far involving a CYP3A substrate showed no 
interaction between ciclosporin and cranberry juice [80]. Although ciclosporin was a reasonable drug to test the 
effects of pomelo juice (described in Section 3.2.2), this drug was not ideal to test for a potential 'cranberry juice 
effect,, as it is not yet known whether cranberry juice modulates P-gp. Thus, it seems premature to initiate 
evaluation of the drug interaction potential of cranberry juice in humans using a dual CYP3A/P-gp substrate. In 
addition, as recognized by Aston et al. 1921, a much smaller quantity of cranberry juice (single glass, 240 ml) 
was consumed by the subjects in the clinical study compared with individuals taking the juice chronically for 
UTI prevention (> 2 — 3 glasses/day). Indeed, assuming an average body weight of a rat of 0.25 kg, the volume 
of juice given in the rat study (2 ml) [911 scales to 560 ml of juice for a 70-kg person, whIch is equivalent to 2 
— 3 glasses of juice. Finally, as was the case for several previously described drug—fruit juice interaction 
studies, the cranberry juice used was not characterized for potential causative ingredients (e.g., major 
flavonoids, proanthocyanidins). Indeed, as Uesawa and Mohri [91] articulated, 'Naturally, the constituents of 
cranberry juice depend on the raw material and the manufacturing process. Discrepancies may therefore be 
due to the differences in the cranberry juice brands used by the researchers . Although potential CYP3A 
inhibitory components in cranberry juice have yet to be identified, our extensive literature search, which 
included the use of natural products chemistry-specific search tools, such as the Dictionary of Natural Products 
and NAPRALERT, indicated that, of the > 150 compounds that have been identified in cranberry, none are 
furanocoumarins. As such, cranberry juice could contain nonfuranocoumarin-derived CYP3A inhibitors with 
unknown, or even known, mechanisms of action. 
 
Several case reports (n = 8) have suggested an interaction between the anticoagulant, warfarin, and cranberry 
juice [92J, in which the International Normalized Ratio, an indicator of anticoagulation status, increased to 
supratherapeutic values; in one case, the International Normalized Ratio increased to > 50, and the patient 
subsequently died from hemorrhage [93]. Warfarin, whose oral bioavailability exceeds 90%, exists as a racemic 
mixture, of which the more pharmacologically active (S)-enantiomer is metabolized primarily by hepatic 
CYP2C9. Accordingly, one proposed mechanism underlying this potentially lethal drug—diet interaction 
involves inhibition of CYP2C9 by components in cranberry juice. The one clinical study that used the CYP2C9 
substrate, flurbiprofen, indicated no interaction with cranberry juice (Table 1) [94]. As with the ciclosporin 
study, the subjects were given only one glass of cranberry juice, and the juice was not characterized for poten-
tial causative ingredients. Taken together, more rigorous studies are warranted to rule out conclusively whether 
or not cranberry juice has drug interaction potential. 
 
3.5 Pomegranate juice 
Pomegranate juice has been touted by the media as a 'super- food, due to its antioxidant and chemoprevention 
properties [202] and to the scientific evidence showing its promise in a variety of conditions, including prostate 
cancer [95] and heart disease [96,97]. Pomegranate is rich in two types of polyphenolic compounds: 
anthocyanins, which give the fruit/juice its red color; and hydrolyzable tannins, which account for 92% of the 
antioxidant activity of the whole fruit 198]. Although this seemingly exotic juice has shown promise to have 
several health benefits, pomegranate juice may also interact with certain medications. For example, 
pomegranate juice was tested recently for its inhibitory effects towards the metabolism of the antiseizure agent 
and CYP3A substrate carbamazepine [99J. These investigators demonstrated this juice to be as effective as 
grapefruit juice in inhibiting carbamazepine metabolism, both in vitro using human liver microsomes, and in 
vivo in rats given the drug orally 199l. As has been demonstrated repeatedly with grapefruit juice and related 
citrus juices in humans, pomegranate juice appeared to inhibit only enteric CYP3A in rats, as exemplified by a 
lack of an effect on drug systemic half-life. Moreover, the average concentration—time profile of 
carbamazepine with pomegranate juice was superimposable with that of grapefruit juice. Compared with water, 
both juices significantly increased average AUC by 50% (Table 1). Finally, an experiment with closed in situ 
intestinal loops further indicated that pomegranate juice did not alter the absorption of carbamazepine, which is 
not a substrate for P-gp [100,101]. Although potential causative ingredients in pomegranate juice were not 
identified, these results suggest that the juice contains potent CYP3A inhibitors that could enhance the systemic 
exposure of clinically relevant substrates in humans. Of the > 100 compounds that have been identified in 
pomegranate (Punka granatum), none are furanocoumarins 1102l. As is the case with cranberry juice, this 
observation, coupled with the fact that the pomegranate is not a citrus fruit, renders furanocoumarins unlikely to 
be the active CYP3A inhibitors. Thus, pomegranate juice could also contain nonfuranocoumarins with known 
and/or unknown mechanisms of action. Whether or not this increasingly popular juice interacts with drugs in 
humans remains to be determined. Again, as with all drug interaction studies involving natural products, it will 
be important to first characterize the juice for potential causative ingredients before testing, both in vitro and in 
vivo, to allow for between-study comparisons. 
 
4. Conclusion 
The small intestine can represent a major organ of first-pass drug elimination, the means of which occurs 
primarily via metabolism. As a consequence, because the small intestine and liver are arranged in series (Figure 
1), drugs can undergo sequential, presystemic elimination before entering the general circulation. For many 
drugs, the extent of first-pass elimination can be large enough to reduce clinical effectiveness. Drugs with a 
narrow therapeutic window are especially vulnerable to this clinical problem and include several immuno-
suppressants and chemotherapeutic agents, many of which are substrates for the prominent drug-metabolizing 
enzyme, CYP3A, which is expressed in high abundance in the small intestine, in addition to the liver. Thus, 
inhibition of CYP3A by drugs or other xenobiotics can significantly elevate circulating drug concentrations, 
which can in turn lead to an enhanced pharmacological or a toxic biological response. 
 
In addition to drugs, some diet-derived xenobiotics have been shown to inhibit CYP3A-mediated metabolism. 
Most notably, grapefruit juice has been demonstrated, unequivocally, to inhibit the first-pass metabolism of an 
array of CYP3A substrates. Drug—grapefruit juice interactions are unique in that, when the juice is consumed 
in usual volumes, inhibition occurs only in the small intestine; for some drugs, the consequences of the 
interaction can be clinically significant. Compounds that have been established as major mediators of the 
grapefruit juice effect include furanocoumarins, which inhibit CYP3A activity by multiple mechanisms. 
Furanocoumarins have also been demonstrated to inhibit P-gp and the uptake transporter, OATP, but the 
collective data so far remain conflicting. Nevertheless, the identification of furanocoumarins as important 
causative ingredients has led to the identification of other citrus juices with interaction potential (e.g., Seville 
orange and pomelo juice). Sweet orange juice, which does not contain furanocoumarins, has also been shown to 
alter drug systemic exposure, presumably via inhibition of enteric OATP, P-gp and/or other uptake/efflux trans-
porters. Candidate inhibitors include polymethoxyflavones, which do not inhibit CYP3A. Collectively, the 
effect of citrus juices on drug disposition is complex, involving multiple mechanisms and multiple causative 
ingredients. 
 
Drug juice interactions may not be restricted to citrus fruits. For example, cranberry juice and pomegranate 
juice have been shown to inhibit enteric CYP3A-mediated metabolism in vivo in rats. Although the one 
published clinical study so far involving cranberry juice and a CYP3A (and P-gp) substrate, ciclosporin, showed 
no interaction, additional studies are required to conclusively rule out whether cranberry juice has drug 
interaction potential. Likewise, further research is required to determine whether pomegranate juice has drug 
interaction potential in humans. 
 
Although the identification of specific dietary substances capable of altering drug disposition has been 
stimulated by the discovery of the grapefruit juice effect, progress in this crucial area of pharmacotherapy 
continues to remain sluggish. Identification of components responsible for drug—diet interactions is especially 
challenging. Unlike regulated drug products, of which the contents and potential interacting components are 
well understood, this is generally not the case for nonregulated products, particularly dietary substances. Taken 
together, the authors contend that a multidisciplinary, translational research approach, one that involves the 
collective expertise of drug metabolism scientists and natural products chemists, is required to fully delineate 
these relatively unexplored types of drug interactions. Such a multidisciplinary approach should enable, 
prospectively, the identification of clinically important drug—diet interactions. Indeed, as has been 
recommended for drug—herbal interactions [76l, journal editors have the opportunity to be especially 
influential in requiring a causative ingredient/pharmacokinetic outcome relationship as a requirement for 
publication, regardless of whether or not the clinical outcome is positive or negative. 
 
5. Expert opinion 
Interindividual variation in response to therapeutic agents is an ongoing problem in clinical practice. Genetic, 
pathophysiologic and environmental factors all contribute to this variation in response, which is in part due to 
the large interindividual variation in the body,s ability to rid itself of xenobiotics via metabolism and/or 
excretion. Of these factors, those derived from the environment perhaps have the greatest iníluence on drug 
elimination processes in the intestine, as the majority of these factors, especially drugs and dietary components, 
enter the body by the oral route and are subsequently absorbed by the enterocytes, which express a sundry of 
drug-metabolizing enzymes and transporters that determine, at least in part, the extent of drug systemic 
exposure. Thus, the likelihood of interactions between drugs and dietary components capable of modulating 
these enteric enzymes/transporters occurs wIth every meal. 
 
The potential for interactions between drugs and dietary components is much greater and perhaps more 
challenging to predict than that between drugs, as interindividual variation in dietary habits is substantial. To 
investigate suspected drug—diet interactions appropriately, a more rigorous approach is required. Simply 
buying a natural product (juice, food, herb) off the shelf and testing it, both in vitro and in vivo, without 
considering the chemical makeup of that substance, provides no basis for comparison between studies, which in 
turn creates confusion in the literature. As a consequence, one is left without a firm recommendation regarding 
whether a specific food should be avoided while taking certain medications. 
 
In addition to the drug—fruit juice interactions highlighted in this review, numerous other potential drug—diet 
interactions are projected to emerge, especially with the growing movement toward natural product remedies, 
often as an adjuvant to conventional medicine that is rarely disclosed to the physician or pharmacist [1031. As a 
consequence, public health suffers because there will be an ever-increasing need to identify the causative 
ingredients contained in the natural product, as well as to discern the mechanisms underlying these potential 
drug—diet interactions. However, before initiating such research, it is imperative to design studies, whether in 
vitro or in vivo, in a manner that accounts for the variable composition of bioactive components contained in the 
'natural, study materials. Even for the same species of plant, the concentrations of bioactive compounds can 
vary throughout the growing season 1104,1051; distinct plant parts (e.g., root versus stem versus leaf) produce 
and store compounds differently 1105,1061, and varying soil, water, sunlight and geographic conditions can 
alter the relative concentration of a plant,s chemical constituents 11071. Despite the fact that these variables are 
well known to anyone who drinks wine, harvested from the same vines, bottled by the same company, but 
produced in two different years, food and herbal materials are too often treated in the scientific literature, 
erroneously, as if they are all identical. Although this may be the standard procedure when examining a 
potential interaction between two drugs, which are manufactured according to good manufacturing practices to 
ensure that every lot is identical, evaluation of a potential interaction between a drug and dietary substances 
(e.g., juice, food, herb), which by their very nature are not identical, requires more sophistication to ensure that 
the results are both reproducible within a study and, perhaps more importantly, comparable between studies. 
Therefore, to elucidate mechanisms underlying drug—diet interactions, it is imperative to examine the natural 
product in a rigorous manner that scrutinizes the metabolic consequences of its consumption in the context of its 
unique chemical makeup. Such information would provide a basis for between-study comparisons, and most 
importantly, provide critical knowledge regarding whether a specific dietary component can be taken safely 
with certain medications. 
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